Lung Cancer Trial, Recruiting (NCT06930807)

Lung Cancer Trial, Recruiting NCT06930807 Sponsor: Peking University People's Hospital Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06930807 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), at an early to moderate stage (classified as stage IA to IIIA), who are planning to have surgery to remove the cancer or to receive treatment before surgery.
People whose lung scan shows a solid growth larger than 1 cm or a faint, hazy growth (called a ground-glass nodule) larger than 1.5 cm.
People who have not had any other type of cancer in the past 5 years (other than non-small cell lung cancer).
People whose tissue samples are well preserved and whose medical imaging records are available for review.

Who may not be able to join:

People under 18 years of age.
People whose non-small cell lung cancer has been classified as a more advanced stage (stage IIIB to IV) based on laboratory examination of tissue.
People whose test results show that their cancer is not actually non-small cell lung cancer.
People who have been diagnosed with another type of cancer within the past 5 years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kezhong Chen, MD, Peking University People's Hospital

Phone: +86-010-88325983

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06930807

Sponsor: Peking University People's Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +86-010-88325983

More information: https://clinicaltrials.gov/study/NCT06930807

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), at an early to moderate stage (classified as stage IA to IIIA), who are planning to have surgery to remove the cancer or to receive treatment before surgery.
People whose lung scan shows a solid growth larger than 1 cm or a faint, hazy growth (called a ground-glass nodule) larger than 1.5 cm.
People who have not had any other type of cancer in the past 5 years (other than non-small cell lung cancer).
People whose tissue samples are well preserved and whose medical imaging records are available for review.

Who may not be able to join:

People under 18 years of age.
People whose non-small cell lung cancer has been classified as a more advanced stage (stage IIIB to IV) based on laboratory examination of tissue.
People whose test results show that their cancer is not actually non-small cell lung cancer.
People who have been diagnosed with another type of cancer within the past 5 years.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University People's Hospital

Registry

ClinicalTrials.gov

Start date

25 March 2025

Est. completion

31 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Two-year recurrence-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov